The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9% in the placebo group and 21.9% in the interferon beta-la-treated group. Interferon beta-la treatment produced a significant delay in time to sustained EDSS progression ( p equals 0.02). The primary outcome variable was time to sustained disability progression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS). Interferon beta-la, 6.0 million units (30 μg), was administered by intramuscular injection weekly.
#Pasteur roland dalo 2016 trial#
Three hundred one patients with relapsing multiple sclerosis were randomized into a double-blinded, placebo-controlled, multicenter phase I11 trial of interferon beta-la. The purpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations.
0 kommentar(er)
